CNS5:Volunteer Assignments and Opportunities: Difference between revisions
| [checked revision] | [checked revision] |
mNo edit summary |
Editor updated for a page on volunteer assignments |
||
| (8 intermediate revisions by 3 users not shown) | |||
| Line 44: | Line 44: | ||
|6/25/2023 | |6/25/2023 | ||
| | | | ||
| | |COMPLETE | ||
| | | | ||
|Laveniya Satgunaseelan (LS) | |Laveniya Satgunaseelan (LS) | ||
| Line 52: | Line 52: | ||
|[[CNS5:Oligodendroglioma,_IDH-mutant_and_1p/19q-codeleted|Oligodendroglioma, IDH-mutant and 1p/19q-codeleted]] | |[[CNS5:Oligodendroglioma,_IDH-mutant_and_1p/19q-codeleted|Oligodendroglioma, IDH-mutant and 1p/19q-codeleted]] | ||
|Disease | |Disease | ||
|Riley Lochner (trainee) | |Riley Lochner (trainee); | ||
Shashi Shetty (mentor) | |||
|6/7/2022 | |6/7/2022 | ||
| | | | ||
| Line 63: | Line 64: | ||
|[[CNS5:Glioblastoma,_IDH-wildtype|Glioblastoma, IDH-wildtype]] | |[[CNS5:Glioblastoma,_IDH-wildtype|Glioblastoma, IDH-wildtype]] | ||
|Disease | |Disease | ||
| | |Jieying Wu | ||
| | |11/18/2025 | ||
| | |01/15/2026 | ||
|PENDING | |PENDING | ||
| | | | ||
| Line 110: | Line 111: | ||
|5/3/2024 | |5/3/2024 | ||
| | | | ||
|PENDING | |PENDING - email reminder 9/4/2025 | ||
| | | | ||
|LS | |LS | ||
| Line 118: | Line 119: | ||
|[[CNS5:Diffuse_midline_glioma,_H3_K27-altered|Diffuse midline glioma, H3 K27-altered]] | |[[CNS5:Diffuse_midline_glioma,_H3_K27-altered|Diffuse midline glioma, H3 K27-altered]] | ||
|Disease | |Disease | ||
|Laveniya Satgunaseelan | |Laveniya Satgunaseelan | ||
| | | | ||
|12/06/2025 | |||
|PENDING | |PENDING | ||
| | | | ||
| Line 173: | Line 174: | ||
|[[CNS5:Pilocytic_astrocytoma_|Pilocytic astrocytoma]] | |[[CNS5:Pilocytic_astrocytoma_|Pilocytic astrocytoma]] | ||
|Disease | |Disease | ||
| | | | ||
| | |<br /> | ||
| | |||
| | |||
| | | | ||
|LS | |LS | ||
| Line 198: | Line 199: | ||
|15/04/2025 | |15/04/2025 | ||
| | | | ||
|PENDING | |PENDING - email reminder 9/4/2025 | ||
| | | | ||
|LS | |LS | ||
| Line 611: | Line 612: | ||
|[[CNS5:Medulloblastoma,_WNT-activated|Medulloblastoma, WNT-activated]] | |[[CNS5:Medulloblastoma,_WNT-activated|Medulloblastoma, WNT-activated]] | ||
|Disease | |Disease | ||
|Lisa Lansdon, PhD (LGG trainee just finished) | |Lisa Lansdon, PhD (LGG trainee just finished); | ||
Midhat Farooqi, MD (mentor), Children's Mercy Hospital Kansas City | |||
|9/20/21 | |9/20/21 | ||
| | | | ||
| Line 633: | Line 635: | ||
|[[CNS5:Medulloblastoma,_SHH-activated_and_TP53-mutant|Medulloblastoma, SHH-activated and TP53-mutant]] | |[[CNS5:Medulloblastoma,_SHH-activated_and_TP53-mutant|Medulloblastoma, SHH-activated and TP53-mutant]] | ||
|Disease | |Disease | ||
|Hannah Wollenzien | |||
|1/11/2026 | |||
| | | | ||
|Pending | |||
| | | | ||
| | |MS | ||
| | | | ||
| | | | ||
| Line 721: | Line 723: | ||
|[[CNS5:CNS_tumour_with_BCOR_internal_tandem_duplication|CNS tumour with BCOR internal tandem duplication]] | |[[CNS5:CNS_tumour_with_BCOR_internal_tandem_duplication|CNS tumour with BCOR internal tandem duplication]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| Line 797: | Line 799: | ||
|[[CNS5:Pineoblastoma|Pineoblastoma]] | |[[CNS5:Pineoblastoma|Pineoblastoma]] | ||
|Disease | |Disease | ||
|Fang Fang (trainee)+Katie Schieffer (mentor) | |||
|11/19/2025 | |||
|5/15/2026 | |||
|Pending | |||
| | | | ||
| | |LS | ||
| | | | ||
| | | | ||